Investment year: 2018


Immunos Therapeutics AG is leading the next generation of immunotherapies for cancer by developing therapies that have a role in both the innate and adaptive immune system which not only have direct anti-tumor effects but also remodel the tumor microenvironment to enhance the efficacy of existing immunotherapies and improve patient lives. This industry leading portfolio of next generation, novel immunomodulatory proteins targets diverse and key immunoregulatory receptors and exhibit strong anti-tumor responses in multiple cancers with monotherapy and in combination with checkpoint inhibitors (CTLA-4, PD-1, PD-L1) and costimulatory agonists (e.g. 4-1BB).